Opendata, web and dolomites

EIS SIGNED

An innovative, effective and minimally-invasive retinal cell therapy combined with a new injection system for treatment of retinal degenerative diseases.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EIS project word cloud

Explore the words cloud of the EIS project. It provides you a very rough idea of what is the project "EIS" about.

approximately    regard    injections    treat    ivt    drug    adult    ga    ocular    visual    combination    standard    consequence    matrix    dosage    optimal    techniques    leaving    age    chain    office    photoreceptor    multiple    therapeutic    stromal    fact    million    close    everads    bone    cell    safe    iop    setting    amd    escalation    marketing    excellent    treatments    innovation    debilitating    injection    rp    retinal    intravitreal    suffering    trials    severe    retinitis    people    glaucoma    blindness    pigmentosa    obtain    treatment    mscs    macular    first    life    platform    atrophy    human    mesenchymal    billion    hbm    organ    geographic    daily    opportunity    lasting    strategy    performed    invasive    innovative    area    longer    eis    ensures    degenerative    choroidal    supply    ivts    cataract    retina    patients    cells    risk    clinical    vessels    minimally    degeneration    worldwide    80    pressure    reduces    initiated    license    feasibility    plan    registered    disease    impairments    effect    device    transplantation    goto    market    blood    causes    dr    utilizing    drafted    perform    subretinal    marrow   

Project "EIS" data sheet

The following table provides information about the project.

Coordinator
EVERADS THERAPY LTD 

Organization address
address: 27 HABARZEL STREET MIGDALEI ORR BUILDING A 5TH FLO
city: TEL AVIV
postcode: n.a.
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EVERADS THERAPY LTD IL (TEL AVIV) coordinator 50˙000.00

Map

 Project objective

Retinal degenerative disease is a debilitating condition with a major impact on daily life. This includes Geographic Atrophy(GA) - as a consequence of age-related macular degeneration (AMD) - and advanced Retinitis Pigmentosa (RP) - all characterized by photoreceptor loss. In fact, they are the main causes of registered blindness. In this regard, there are no currently effective treatments for patients suffering from GA a and RP, leaving approximately 2.6 million people across Europe and over 5 million worldwide with the risk of developing severe visual impairments. Standard techniques to treat GA and DR, including Intravitreal Injections (IVTs) and subretinal transplantation present major problems associated with them. Everads developed a treatment for macular and retinal degeneration, utilizing the innovative Everads Injection System (EIS), a minimally invasive platform for optimal injection of Adult Bone Marrow Mesenchymal Stromal Cells (hBM-MSCs). Unique treatment approach allows simple, office-based safe transplantation of hBM-MSCs in the matrix between the choroidal blood vessels, providing excellent distribution very close to the target organ (retina) and long-term therapeutic effects, targeting multi-billion market opportunity. The Everads treatment is safe, minimally-invasive, can be performed in an office setting and ensures 80% drug distribution in the retinal area, aiming for longer lasting effect of drug. It also reduces the risk of side effects like increased Intra Ocular Pressure (IOP), glaucoma, cataract typical of IVT injections. During the feasibility assessment, a goto market strategy and a supply chain will be established, and further development plan will be drafted. During the phase 2 of innovation project, Everads will perform further product development and cell distribution and dosage escalation activities. Multiple first in human clinical trials will be initiated to obtain marketing license as a drug-device combination product.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EIS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

Proteus 25 (2018)

Developing the world’s first food wrapping machine with organic film

Read More  

Preemie (2019)

Personalised nutrition of low-birth-weight infants

Read More